tert-butyl (3R)-3-(2-fluoro-5-methylbenzoyl)piperidine-1-carboxylate | 1233236-22-0

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: tert-butyl (3R)-3-(2-fluoro-5-methylbenzoyl)piperidine-1-carboxylate
• CAS: 1233236-22-0
• 化学式: C₁₈H₂₄FNO₃
• 分子量: 321.392
• InChiKey: VXJQKJWQIREYGB-CYBMUJFWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  23
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  46.6
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  tert-butyl (3R)-3-(2-fluoro-5-methylbenzoyl)piperidine-1-carboxylate 、 magnesium,1-methoxybutane,chloride 以 四氢呋喃 为溶剂， 生成
  参考文献：
  名称：

  Design and optimization of renin inhibitors: Orally bioavailable alkyl amines

  摘要：

  Structure-based drug design led to the identification of a novel class of potent, low MW alkylamine renin inhibitors. Oral administration of lead compound 21l, with MW of 508 and IC(50) of 0.47 nM, caused a sustained reduction in mean arterial blood pressure in a double transgenic rat model of hypertension. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.04.140
• 作为产物：
  描述：

  (3R)-3-[(甲氧基甲基氨基)羰基]-1-哌啶羧酸 1,1-二甲基乙酯 、 alkaline earth salt of/the/ methylsulfuric acid 以 四氢呋喃 为溶剂， 生成 tert-butyl (3R)-3-(2-fluoro-5-methylbenzoyl)piperidine-1-carboxylate
  参考文献：
  名称：

  Design and optimization of renin inhibitors: Orally bioavailable alkyl amines

  摘要：

  Structure-based drug design led to the identification of a novel class of potent, low MW alkylamine renin inhibitors. Oral administration of lead compound 21l, with MW of 508 and IC(50) of 0.47 nM, caused a sustained reduction in mean arterial blood pressure in a double transgenic rat model of hypertension. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.04.140

文献信息

• Diaminoalkane Aspartic Protease Inhibitors
  申请人：Baldwin John J.

  公开号：US20090018103A1

  公开（公告）日：2009-01-15

  Diaminoalkanes of Formula I have now been found which are orally active and bind to aspartic proteases to inhibit their activity. They are useful in the treatment or amelioration of diseases associated with elevated levels of aspartic protease activity. The invention also relates to a method for the use of the compounds of Formula I in ameliorating or treating aspartic protease related disorders in a subject in need thereof comprising administering to said subject an effective amount of a compound of Formula I.

  公式I的Diaminoalkanes现已被发现，它们具有口服活性并结合到天冬氨酸蛋白酶以抑制其活性。它们在治疗或改善与天冬氨酸蛋白酶活性升高相关的疾病方面非常有用。本发明还涉及使用公式I化合物治疗或改善需要的天冬氨酸蛋白酶相关疾病的方法，包括向该受体施用公式I化合物的有效量。
• Piperidine and Morpholine Renin Inhibitors
  申请人：Baldwin John J.

  公开号：US20090264432A1

  公开（公告）日：2009-10-22

  Described are compounds which are orally active and bind to renin to inhibit its activity. They are useful in the treatment or amelioration of diseases associated with renin activity. Also described are methods of use of these compounds for treating or ameliorating a renin mediated disorder in a subject.

  描述了一些口服的化合物，它们能够结合到肾素并抑制其活性。它们在治疗或改善与肾素活性相关的疾病方面是有用的。同时描述了使用这些化合物治疗或改善受肾素介导的疾病的方法。
• Diaminoalkane aspartic protease inhibitors
  申请人：Baldwin John J.

  公开号：US20110105506A1

  公开（公告）日：2011-05-05

  Diaminoalkanes of Formula I have now been found which are orally active and bind to aspartic proteases to inhibit their activity. They are useful in the treatment or amelioration of diseases associated with elevated levels of aspartic protease activity. The invention also relates to a method for the use of the compounds of Formula I in ameliorating or treating aspartic protease related disorders in a subject in need thereof comprising administering to said subject an effective amount of a compound of Formula I.

  公式I的二氨基烷已被发现具有口服活性并能结合天冬氨酸蛋白酶以抑制其活性。它们可用于治疗或改善与天冬氨酸蛋白酶活性升高相关的疾病。本发明还涉及一种使用公式I化合物改善或治疗需要的天冬氨酸蛋白酶相关疾病的方法，包括向该受试者施用有效量的公式I化合物。
• US7754737B2
  申请人：——

  公开号：US7754737B2

  公开（公告）日：2010-07-13
• US7858624B2
  申请人：——

  公开号：US7858624B2

  公开（公告）日：2010-12-28